

**CNCR\_32339\_e.Supporting Information\_Table S1. Relationships between clinical response, baseline levels of plasma cytokines/chemokines, PD-1, PD-L1/PD-L2, and other features**

<b>Features</b>	<b>No. of Cases</b>	<b>Responders ( N=12)</b>	<b>Non-responder s (N=12)</b>	<b>P-value</b>
<b>Total N=24</b>				
<u>Gender</u>				
Males	21	11 (52%)	10 (48%)	1.000
Females	3	1 (33%)	2 (67%)	
<u>Age</u>				
< 60 years	5	2 (40%)	3 (60%)	1.000
≥ 60 years	19	10 (53%)	9 (47%)	
<u>Tumor sizes</u>				
< 50 mm	10	5 (50%)	5 (50%)	1.000
≥ 50 mm	14	7 (50%)	7 (50%)	
<u>HCV</u>				
Positive	8	4 (50%)	4 (50%)	1.000
Negative	16	8 (50%)	8 (50%)	
<u>HBV</u>				
Positive	5	3 (60%)	2 (40%)	1.000
Negative	19	9 (47%)	10 (53%)	
<u>Tumor PD-L1</u>				
Positive	3	1 (33%)	2 (67%)	1.000
Negative	6	2 (33%)	4 (67%)	
<u>Plasma TGF-β</u>				
< 200 pg/ml	12	10 (67%)	2 (33%)	<b>0.003</b>
≥ 200 pg/ml	12	2 (18%)	10 (82%)	
<u>Plasma IL-1β</u>				
< 3 pg/ml	15	7 (47%)	8 (53%)	1.000
≥ 3 pg/ml	9	5 (56%)	4 (44%)	
<u>Plasma IL-12</u>				
< 400 pg/ml	15	7 (47%)	8 (53%)	1.000
≥ 400 pg/ml	9	5 (56%)	4 (44%)	
<u>Plasma IL-18</u>				
< 90 pg/ml	11	5 (46%)	6 (54%)	1.000
≥ 90 pg/ml	13	7 (54%)	6 (46%)	

<u>Plasma IL-6</u>				
< 20 pg/ml	14	9 (64%)	5 (36%)	0.214
≥ 20 pg/ml	10	3 (30%)	7 (70%)	
<u>Plasma IFN-γ</u>				
< 10 pg/ml	15	6 (40%)	9 (60%)	0.400
≥ 10 pg/ml	9	6 (67%)	3 (33%)	
<u>Plasma IL-10</u>				
< 15 pg/ml	14	7 (50%)	7 (50%)	1.000
≥ 15 pg/ml	10	5 (50%)	5 (50%)	
<u>Plasma IL-8</u>				
< 20 pg/ml	12	6 (50%)	6 (50%)	1.000
≥20 pg/ml	12	6 (50%)	6 (50%)	
<u>Plasma CXCL9</u>				
< 500 pg/ml	14	6 (43%)	8 (57%)	0.680
≥ 500 pg/ml	10	6 (60%)	4 (40%)	
<u>Plasma CCL4</u>				
< 60 pg/ml	11	6 (55%)	5 (45%)	1.000
≥ 60 pg/ml	13	6 (46%)	7 (54%)	
<u>Plasma CCL5</u>				
< 900 pg/ml	13	7 (54%)	6 (46%)	1.000
≥ 900 pg/ml	11	5 (46%)	6 (54%)	
<u>Plasma PD-1</u>				
< 200 pg/ml	16	8 (50%)	8 (50%)	1.000
≥ 200 pg/ml	8	4 (50%)	4 (50%)	
<u>Plasma PD-L1</u>				
< 200 pg/ml	13	6 (46%)	7 (54%)	1.000
≥ 200 pg/ml	11	6 (54%)	5 (46%)	
<u>Plasma PD-L2</u>				
< 6 ng/ml	12	6 (50%)	6 (50%)	1.000
≥ 6 ng/ml	12	6 (50%)	6 (50%)	

---

**CNCR\_32339\_e.Supporting Information\_Table S2. Relationships between baseline plasma TGF- $\beta$  levels, clinical features, and other biomarkers in 24 HCC patients**

<b>Features</b>	<b>No. of Cases</b>	<b>TGF-<math>\beta</math> &lt; 200 pg/ml (N=12)</b>	<b>TGF-<math>\beta</math> <math>\geq</math> 200 pg/ml (N=12)</b>	<b>P-value</b>
<b>Total N=24</b>				
<u>Gender</u>				
Males	21	11 (52%)	10 (48%)	1.000
Females	3	1 (33%)	2 (67%)	
<u>Age</u>				
< 60 years	5	2 (40%)	3 (60%)	1.000
$\geq$ 60 years	19	10 (53%)	9 (47%)	
<u>Tumor sizes</u>				
< 50 mm	14	7 (50%)	7 (50%)	1.000
$\geq$ 50 mm	10	5 (50%)	5 (50%)	
<u>HCV</u>				
Positive	7	5 (71%)	2 (29%)	0.371
Negative	17	7 (41%)	10 (59%)	
<u>HBV</u>				
Positive	5	2 (40%)	3 (60%)	1.000
Negative	19	10 (53%)	9 (47%)	
<u>Tumor PD-L1</u>				
Positive	3	1 (33%)	2 (67%)	1.000
Negative	6	3 (50%)	3 (50%)	
<u>Plasma IL-1<math>\beta</math></u>				
< 3 pg/ml	15	7 (47%)	8 (53%)	1.000
$\geq$ 3 pg/ml	9	5 (56%)	4 (44%)	
<u>Plasma IL-12</u>				
< 400 pg/ml	15	7 (47%)	8 (53%)	1.000
$\geq$ 400 pg/ml	9	5 (56%)	4 (44%)	
<u>Plasma IL-18</u>				
< 90 pg/ml	11	5 (46%)	6 (54%)	1.000
$\geq$ 90 pg/ml	13	7 (54%)	6 (46%)	

Plasma IL-6

< 20 pg/ml	14	8 (57%)	6 (43%)	0.680
≥ 20 pg/ml	10	4 (40%)	6 (60%)	

Plasma IFN-γ

< 10 pg/ml	15	6 (40%)	9 (60%)	0.400
≥ 10 pg/ml	9	6 (67%)	3 (33%)	

Plasma IL-10

< 15 pg/ml	14	6 (43%)	8 (57%)	1.000
≥ 15 pg/ml	10	6 (60%)	4 (40%)	

Plasma IL-8

< 20 pg/ml	8	5 (63%)	3 (37%)	0.667
≥ 20 pg/ml	16	7 (44%)	9 (56%)	

Plasma CXCL9

< 500 pg/ml	15	6 (40%)	9 (60%)	0.400
≥ 500 pg/ml	9	6 (67%)	3 (33%)	

Plasma CCL4

< 60 pg/ml	11	5 (46%)	6 (54%)	1.000
≥ 60 pg/ml	13	7 (54%)	6 (46%)	

Plasma CCL5

< 900 pg/ml	13	7 (54%)	6 (46%)	1.000
≥ 900 pg/ml	11	5 (46%)	6 (54%)	

Plasma PD-1

< 200 pg/ml	15	7 (47%)	8 (53%)	1.000
≥ 200 pg/ml	9	5 (56%)	4 (44%)	

Plasma PD-L1

< 200 pg/ml	13	5 (38%)	8 (62%)	0.414
≥ 200 pg/ml	11	7 (64%)	4 (36%)	

Plasma PD-L2

< 6ng/ml	12	5 (42%)	7 (58%)	0.684
≥ 6 ng/ml	12	7 (58%)	5 (42%)	

---